Strategic sale Active exit and asset sale to Lucy Scientific Discovery indicates potential licensing, collaboration, or platform acquisition opportunities for psychedelic-based mental health assets.

TBI focus History of brain injury research through BrainStorm Lab and PsyTech acquisition highlights potential to cross-sell neuropsychiatric outcomes and cognitive rehab solutions to TBI-focused clinics and hospitals.

Cannabinoid synergy Partnerships with large food/agribusiness and interest in plant medicines suggest avenues for partnerships with wellness brands, nutraceuticals, and employers prioritizing employee mental health and resilience programs.

Psychedelic leadership Pioneering position in psychedelic medicine for mental health creates demand among research institutions, biotech funds, and pharma developers seeking collaboration, licensing, or co-development deals.

Financial trajectory Modest revenue and existing funding base indicate openness to strategic investments, partnerships, or joint ventures to accelerate clinical programs and bring assets to market faster.